Clinical Trial: Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07445048) titled 'Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma' on Feb. 10.

Brief Summary: A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Bemcentinib in high-risk patients with head and neck squamous cell carcinoma who are ineligible for cisplatin chemotherapy.

The primary endpoint is disease-free survival (DFS). A total of 185 patients will be enrolled in both the study group and the control group, respectively, with a tot...